David R. Minor - Concepedia

Author

David R. Minor

Also Known As

D Almeida, D Minor, D R Minor, D. Minor, D. R. Minor, D.R. Minor, DAVID R. MINOR, David J. Minor, David Minor, David R Minor

116

Publications

11.4K

Citations

H-Index

Concepts

All Affiliations

California Pacific Medical Center Angeles Clinic and Research Institute Dana-Farber Cancer Institute Northern California Melanoma Center Moffitt Cancer Center

About

David R. Minor is an author at California Pacific Medical Center specializing in medicine, oncology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	29	5K
2	Health Sciences	11	11	3.1K
3	Allergy	4	4	288
4	Public Health	1	1	51
5	Cell Biology	1	1	117

David R. Minor

Publications

10.9K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma Michael A. Postow, Jason Chesney, Anna C. Pavlick, New England Journal of Medicine	2015	2.7K
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, The Lancet Oncology Checkmate 037MedicineMelanomaNivolumab Versus ChemotherapyImmune Checkpoint Inhibitor	2015	2.6K
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial F. Stephen Hodi, Jason Chesney, Anna C. Pavlick, The Lancet Oncology OncologyMelanomaClinical TrialsImmune Checkpoint InhibitorDermatology	2016	967
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma Jeffrey S. Weber, John A. Thompson, Omid Hamid, Clinical Cancer Research	2009	563
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma Igor Puzanov, Mohammed Milhem, David R. Minor, Journal of Clinical Oncology	2016	542
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial James Larkin, David R. Minor, Sandra P. D’Angelo, Journal of Clinical Oncology	2017	497
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma Paolo A. Ascierto, David R. Minor, Antoni Ribas, Journal of Clinical Oncology	2013	422
Sunitinib Therapy for Melanoma Patients with <i>KIT</i> Mutations David R. Minor, Mohammed Kashani–Sabet, M Garrido, Clinical Cancer Research	2012	191
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609 Ahmad A. Tarhini, Sandra J. Lee, F. Stephen Hodi, Journal of Clinical Oncology	2019	168
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma John F. Thompson, Sanjiv S. Agarwala, B. Mark Smithers, Annals of Surgical Oncology	2014	146

Page 1